Results 161 to 170 of about 154,826 (359)
Abstract Background Schwann cells provide peripheral nerve trophic support, myelinate axons, and assist in repair. However, Schwann cell repair capacity is limited by chronic injury, disease, and aging. Schwann cell reprogramming is a cellular conversion strategy that could provide a renewable cell supply to repair injured nerves.
Lauren Belfiore +7 more
wiley +1 more source
Presentation of Multiple Myeloma with Extramedullary Plasmacytoma After Autologous Stem Cell Transplantation [PDF]
Yağmur BERKTAŞ +2 more
openalex +1 more source
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli +17 more
wiley +1 more source
Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma [PDF]
Bhawna Sirohi +8 more
openalex +1 more source
Amphibian‐derived peptide RL‐QN15 activates the Wnt/β‐catenin signaling pathway by interacting with the FZD8 membrane receptor, promoting epidermal stem cells proliferation, migration, stemness, and EMT processes, thus promoting skin wound healing.
Yuansheng Li +15 more
wiley +1 more source
Harnessing Piezoelectric Biomaterials for Pathogenic Eradication and Tissue Regeneration
This review highlights recent advances in piezoelectric biomaterials for antibacterial therapy and tissue regeneration, discussing material classifications, catalytic mechanisms, property enhancements, biomedical applications, and future challenges in clinical translation.
Wenxuan Mao +11 more
wiley +1 more source
Advanced extracellular vesicle immunotherapy
A diagrammatic depiction of the therapeutic applicability of extracellular vesicles (EVs) in immunotherapy. This review explores the dual roles of tumor‐derived and immune cell‐derived EVs in cancer immunotherapy, discusses recent progress in EV engineering that improve their clinical utility, and evaluates their potential to augment existing ...
Jingjing Zhang +6 more
wiley +1 more source
What's New? Patients with mantle cell lymphoma showing disease progression within 24 months of primary treatment have worse prognosis than patients with later progression. This population‐based study suggests that although early relapse is especially serious, disease progression more than 6 years after treatment still leads to worse survival than the ...
Sara Ekberg +5 more
wiley +1 more source

